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Cardiac Drugs
for Treatment of Canine Heart Failure
C A R D I O L O G Y
Mark A. Oyama, DVM, Diplomate ACVIM (Cardiology), University of Pennsylvania
Degenerative mitral valve disease (DMVD) and dilated cardiomyopathy
(DCM) are common cardiac diseases in adult dogs. Both diseases can lead to
heart failure and loss of quality and quantity of life.
m e d i c a t i o n s
Various cardiac drugs prolong sur-vival and many others help allevi-ate clinical signs.
D I U R E T I C S
INDICATIONS
Diuretics are a mainstay of therapy in
dogs with congestive heart failure (CHF)
due to DMVD or DCM.
ADMINISTRATION
Bolus injections of furosemide (2–4
mg/kg Q 2 H) are used in dogs with
respiratory distress secondary to acute
heart failure until respiratory rate and
effort begin to improve.
Alternatively, furosemide can be given as
a constant rate infusion. Purported
advantages of furosemide infusion over
intermittent boluses include enhanced
natriuresis and diuresis and less urinary
potassium loss. I recommend using 0.66
to 1 mg/kg/H, monitoring respiratory
rate every hour.
Once acute heart failure is resolved,
chronic oral therapy with furosemide
(1–2 mg/kg Q 12 H) is initiated. As
disease progresses, many dogs require
escalating doses of furosemide to sup-
press signs of congestion and total
doses of 6 to 8 mg/kg Q 24 H are not
uncommon.
CONSIDERATIONS
In experimental studies, dogs have rap-
idly become resistant to chronic
furosemide. In clinical patients, high
doses of furosemide are often associated
with diminishing polyuria and polydipsia
and recurrent episodes of heart failure.
In these cases, additional diuretics
(hydrochlorothiazide or a hydrochloro-
thiazide–spironolactone combination,
0.5–1 mg/kg Q 24–48 H) help restore
diuretic response. In most cases, the
additional diuretics are added to the
existing furosemide regimen.
In dogs with advanced disease, and par-
ticularly in cases of right heart failure,
bioavailability of oral medications is
likely reduced. Daily subcutaneous injec-
tions of furosemide can be used in place
of oral administration and are often
associated with restoration of copious
diuresis.
MONITORING
In all instances of diuretic use, renal
function should be closely monitored.
A C E I N H I B I T O R S
INDICATIONS
Severe heart disease is generally
associated with activation of the renin–
angiotensin–aldosterone system (RAAS),
which promotes fluid retention, vasocon-
striction, and myocardial and vascular
remodeling. Use of ACE inhibitors in
dogs with CHF is associated with
improved quality of life and survival;
however, data in support of this state-
ment are less robust for dogs with DCM
than for dogs with DMVD. When diure-
tics such as furosemide are adminis-
tered, the reduction of plasma volume
further stimulates RAAS activity and
coadministration with an ACE inhibitor is
generally recommended.
ADMINISTRATION
There are a variety of ACE inhibitors
available, including enalapril, benazepril,
ramapril, and lisinopril (Table). Differ-
ences are relatively minor, mainly involv-
ing route of metabolism/excretion and
ACE = angiotensin-converting enzyme; CHF = congestive heart failure; DMVD = degenerative mitral valve disease; DCM = dilated cardiomyopathy;
RAAS = renin–angiotensin–aldosterone system
Visit cliniciansbrief.com/subscribe to get your OWN FREE
digital subscription to Clinician’s Brief.
PI
M
OB
EN
DA
N
medicat ions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N AV C c l in ic ian’s br ief . oc tober . 2009. . . . .57
Table.
Commonly Used ACE Inhibitors in Dogs with DMVD & DCM
Drug Dose Tablet Sizes
Benazepril 0.25–0.5 mg/kg Q 24 H 5, 10, 20, 40 (mg)
Enalapril 0.5 mg/kg Q 12–24 H 2.5, 5, 10, 20 (mg)
Lisinopril 0.5 mg/kg Q 24 H 2, 5, 10, 20, 40 (mg)
Ramipril 0.125 mg/kg Q 24 H 1.25, 2.5, 5 (mg)
c o n t i n u e s
lipophilicity. From a clinical standpoint,
many cardiologists consider them to be
interchangeable. In the United States, the
two most commonly used ACE inhibitors
are enalapril and benazepril; both are
associated with clinical benefit in dogs
with signs of heart failure.
CONSIDERATIONS
In dogs with DMVD, the use of ACE
inhibitors in those without clinical signs
remains controversial. Two well-designed
studies offer slightly different perspectives:
One study in Cavalier King Charles spaniels
with mild–moderate DMVD clearly indi-
cated that enalapril did not delay onset of
CHF. Another study involving dogs of many
different breeds and more advanced DMVD
also failed to show benefit with respect to
the study’s primary endpoint; however,
analysis of several secondary endpoints
suggested that dogs that received enalapril
avoided heart failure longer than dogs that
did not.
In my opinion, if ACE inhibitors delay heart
failure in dogs with DMVD that show no
clinical signs, the effect is inconsistent
from individual to individual, relatively
small, and unlikely to dramatically change
progression of disease. In dogs with severe
heart enlargement and at high risk for CHF,
I prefer to use an ACE inhibitor in tandem
with low-dose diuretic therapy (furosemide,
1 mg/kg Q 24 H), as this more likely
reduces plasma volume, intracardiac pres-
sure, and risk of CHF than using an ACE
inhibitor alone.
In human patients with asymptomatic
DCM, early use of ACE inhibitors is widely
recommended. In veterinary medicine,
large-scale trials are lacking; however, a
small study indicated that ACE inhibitors
delayed onset of heart failure in Doberman
pinschers with DCM. Thus, in dogs with
DCM, I recommend use of ACE inhibitors
prior to onset of clinical signs.
MONITORING
Adverse effects of ACE inhibitor treatment
are relatively rare, but clinically significant
renal dysfunction can occur. Less com-
monly, systemic hypotension or electrolyte
imbalances are encountered. Renal func-
tion should be evaluated both before and
after initiation of ACE inhibitors and at 3-
to 6-month intervals thereafter.
P I M O B E N D A N
INDICATIONS
Both DMVD and DCM are associated with
progressive loss of myocardial contractility.
Poor contractility is much easier to detect in
dogs with DCM as opposed to DMVD, where
the presence of a large degree of mitral
regurgitation often confounds routine echo-
cardiographic evaluation of contractility.
Pimobendan is a positive inotrope and
increases contractility through a mecha-
nism different from that of traditional
inotropes such as digoxin—the advantage
of which is increased contractility without
significant increases in myocardial oxygen
demand. Pimobendan also relaxes vascular
smooth muscle and elicits modest arterial
vasodilation; this dual “inodilating” action
is unique. Pimobendan improves survival
and quality of life in dogs with DMVD, and
very likely does the same in dogs with
DCM.
ADMINISTRATION
The recommended dose is 0.5 mg/kg per
day, divided into 2 doses that do not neces-
sarily need to be equal.
CONSIDERATIONS
The benefits of pimobendan have been
substantiated in dogs showing clinical
signs associated with heart disease due to
DMVD and DCM; treatment with this agent
is recommended only if clinical signs are
evident. Thus, in the majority of instances,
pimobendan is prescribed only if and
when dogs experience congestive heart
failure and its attendant clinical manifesta-
tions (eg, cough, dyspnea, tachypnea).
Less commonly, dogs with exercise intoler-
ance or syncope are also candidates for
treatment. Currently, no evidence exists for
the use of pimobendan in dogs with DMVD
or DCM prior to the onset of clinical signs.
MONITORING
Pimobendan is generally well tolerated in
dogs and no specific monitoring recom-
mendations accompany its use.
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Congestive Heart Failure
Mild Severe CHF
Congestive Heart FailureNo Clinical Signs
No Clinical Signs
ACE Inhibitor
Furosemide
Pimobendan
Spironolactone
Hydrochlorothiazide
ACE Inhibitor
Furosemide
Pimobendan
Spironolactone
Hydrochlorothiazide
Beta-blockers
Treatment scheme for dogs with DMVD as they progress from mild to severe disease (without clinical
signs) to CHF and finally to advanced refractory disease. Recommendations in green are supported by
veterinary trials; recommendations in orange are advocated by the author.
Treatment scheme for dogs with DCM as they progress from mild to severe disease (without clinical
signs) to CHF and finally to advanced refractory disease. Recommendations in green are supported by
veterinary trials; recommendations in orange are advocated by the author.
Refractory CHF
Mild Severe CHF Refractory CHF
Treatment Schemes:
Degenerative Mitral Valve Disease & Dilated Cardiomyopathy
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INDICATIONS
Spironolactone is a relatively weak potas-
sium-sparing diuretic, and its potency pre-
vents its use as the sole diuretic agent in
dogs with CHF. The value of spironolactone
most likely lies in its action as a specific
aldosterone antagonist. Aldosterone is a
part of the aforementioned RAAS and pro-
motes fluid retention and vascular and
myocardial remodeling. Interestingly, in
both humans and dogs with heart disease,
aldosterone can be elevated despite the use
of ACE inhibitors. Suppression of this
“aldosterone escape” by spironolactone is
associated with reduced morbidity and
improved survival in dogs with DMVD.
ADMINISTRATION
In dogs with signs of heart failure, spirono-
lactone (1–2 mg/kg Q 12 H) is recom-
mended in addition to furosemide, ACE
inhibitors, and pimobendan. In Europe,
where spironolactone is specifically
approved for use in dogs with DMVD, the
recommended dose is 2 mg/kg Q 24 H. In
the United States, many cardiologists use a
lower dose of spironolactone (0.5–1 mg/kg
day) or spironolactone coupled with a thi-
azide diuretic such as hydrochlorothiazide.
MONITORING
Adverse effects can include hyperkalemia
(especially in the face of concurrent ACE
inhibitor) and azotemia, and routine renal
and electrolyte monitoring is recom-
mended.
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Sympathetic tone is chronically elevated
in dogs with DMVD and DCM and is
thought to contribute to disease progres-
sion. In humans, plasma norepinephrine
is a powerful predictor of morbidity and
mortality. However, routine use of beta-
blockers in veterinary medicine is hin-
dered by lack of well-controlled clinical
trials and risk for adverse events when
initiating therapy, especially in dogs with
advanced disease. In humans, beta-block-
ade is recommended in virtually all
instances of reduced contractility, such as
occurs in DCM. Thus, administration of
beta-blockers is advocated by many car-
diologists in dogs with DCM.
ADMINSTRATION
Because of the risk for acute slowing of
heart rate and decreases in contractility,
treatment with beta-blockers must be
performed with caution. Typically, the
dose is up-titrated over 4 to 6 weeks with
close monitoring of heart rate, respira-
tory effort, and blood pressure. Titration
is best tolerated in dogs with relatively
early DCM.
CONSIDERATIONS
In dogs with DMVD, the use of beta-
blockers is controversial and no consen-
sus recommendations can be made.
MONITORING
Practitioners who use beta-blockers must
be prepared to monitor dogs closely and
to deal with acute decompensation
should it occur. Consultation with a cardi-
ologist is recommended. 
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Take Note
Drug doses listed in this
article are guidelines for
the “typical” dog with
heart failure. They may need to
be adjusted based on the
patient’s severity of signs, renal
function, concurrent disease, and
response to initial treatment.
When prescribing medications to
dogs with congestive heart fail-
ure due to DMVD or DCM, there
is broad consensus that
combination therapy with
furosemide, an ACE
inhibitor, and pimobendan
is beneficial.
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ACE = angiotensin-converting enzyme; CHF = congestive heart failure; DMVD = degenerative mitral valve disease;
DCM = dilated cardiomyopathy; RAAS = renin–angiotensin–aldosterone system
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CAUTION: Federal (USA) law restricts this drug to 
use by or on the order of a licensed veterinarian. 
DESCRIPTION: Methimazole is a thioureylene 
antithyroid drug, which inhibits the synthesis of 
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event of accidental ingestion/overdose, seek medical 
advice immediately and show the product label  
to the physician. 
PRECAUTIONS: Use of FELIMAZOLE Coated 
Tablets in cats with renal dysfunction should be 
carefully evaluated.  Reversal of hyperthyroidism  
may be associated with decreased glomerular 
ltration rate and a decline in renal function, 
unmasking the presence of underlying renal disease.  
Cats on methimazole therapy should be monitored 
closely for any sign of illness including fever, 
lymphadenopathy, or signs of anemia, as these  
may be associated with serious adverse reactions. 
 
ADVERSE REACTIONS: The most common  
adverse reactions reported are lethargy, anorexia, 
vomiting, diarrhea/loose stool, abnormal vocalization, 
and self-induced excoriations of the head and 
neck. Serious, but less common, adverse reactions 
may include lymphadenopathy, hepatopathy, 
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Canine Cardiac Drugs Approved by the FDA
In the United States extralabel use of animal and human drugs is permitted in non–food-
producing animal practice except when public health is threatened. However, it should be
noted that products approved by the FDA for a particular species and use have gone
through a rigorous review process.
Benazepril Not in U.S.; approved in Europe & Canada
Enalapril Enacard (merial.com)
Furosemide Lasix (intervet.com); Disal (boehringer-ingelheim.com)
Hydrochlorothiazide Only approved for use in cattle (Hydrozide; merial.com)
Lisinopril Not in U.S.
Pimobendan Vetmedin (boehringer-ingelheim.com)
Ramapril Not in U.S.; approved in Europe
Spironolactone Not in U.S.; approved in Europe
